| 1 WOMAC total score (0 to 100 mm VAS; change from baseline) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 1.1 5 to 13 weeks post‐injection |
1 |
222 |
Mean Difference (IV, Fixed, 95% CI) |
‐24.40 [‐56.32, 7.52] |
| 1.2 14 to 26 weeks post‐injection |
1 |
222 |
Mean Difference (IV, Fixed, 95% CI) |
‐15.30 [‐47.95, 17.35] |
| 2 Patient global assessment (0 to 100 mm VAS; change from baseline) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 2.1 5 to 13 weeks post‐injection |
1 |
222 |
Mean Difference (IV, Fixed, 95% CI) |
‐8.80 [‐16.61, ‐0.99] |
| 2.2 14 to 26 weeks post‐injection |
1 |
222 |
Mean Difference (IV, Fixed, 95% CI) |
‐7.30 [‐15.17, 0.57] |
| 3 Physician global assessment (0 to 100 mm VAS; change from baseline) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 3.1 5 to 13 weeks post‐injection |
1 |
222 |
Mean Difference (IV, Fixed, 95% CI) |
‐2.40 [‐8.47, 3.67] |
| 3.2 14 to 26 weeks post‐injection |
1 |
222 |
Mean Difference (IV, Fixed, 95% CI) |
‐3.40 [‐10.06, 3.26] |
| 4 WOMAC pain on standing (0 to 100 mm VAS; change from baseline) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 4.1 5 to 13 weeks post‐injection |
1 |
194 |
Mean Difference (IV, Fixed, 95% CI) |
‐7.5 [‐15.98, 0.98] |
| 4.2 14 to 26 weeks post‐injection |
1 |
194 |
Mean Difference (IV, Fixed, 95% CI) |
‐4.0 [‐12.68, 4.68] |
| 5 Number of patients with a 20% improvement from baseline in WOMAC pain score |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 5.1 5 to 13 weeks post‐injection |
1 |
194 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.26 [1.07, 1.49] |
| 5.2 14 to 26 weeks post‐injection |
1 |
194 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.06 [0.87, 1.29] |
| 6 Number of patients with a 40% improvement from baseline in WOMAC pain score |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 6.1 5 to 13 weeks post‐injection |
1 |
194 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.24 [0.98, 1.56] |
| 6.2 14 to 26 weeks post‐injection |
1 |
194 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.19 [0.92, 1.55] |
| 7 Number of patients with a 50% improvement from baseline in WOMAC pain score |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 7.1 5 to 13 weeks post‐injection |
1 |
194 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.24 [0.94, 1.63] |
| 7.2 14 to 26 weeks post‐injection |
1 |
194 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.25 [0.93, 1.69] |
| 8 Safety: total withdrawals overall |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 9 Safety: total withdrawals due to lack of efficacy |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 10 Safety: number of patients reporting adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 11 Safety: number of patients with gastrointestinal adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 12 Safety: number of patients with general body adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 13 Safety: number of patients with infections |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 14 Safety: number of patients with musculoskeletal adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 15 Safety: number of patients with nervous system adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 16 Safety: number of patients with respiratory adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 17 Safety: number of patients with skin adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
